Phase II study of bisantrene administered by continuous 72-hour infusion for advanced pancreatic adenocarcinoma.
Eighteen ambulatory patients who had proven metastatic adenocarcinoma of the pancreas and measurable disease but no previous chemotherapy were treated with bisantrene given by constant central intravenous infusion over 72 hours at a total dose of 300 mg/m2 repeated every 3 to 4 weeks. No objective regression was seen. The median interval to progression was 6 weeks; the median survival was 14 weeks. Primary toxic reactions were nausea, vomiting, and leukopenia. In no instance were these life-threatening. When administered by the method we used, bisantrene cannot be recommended for treatment of advanced pancreatic adenocarcinoma.
Marschke
R F
RF
Central Plains Clinic, Ltd., Sioux Falls, South Dakota.
Kvols
L K
LK
Cullinan
S A
SA
Laurie
J A
JA
Mailliard
J A
JA
Tschetter
L K
LK
O'Connell
M J
MJ
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality; D000873:Anthracenes / Q000008:administration & dosage / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004341:Drug Evaluation; D007260:Infusion Pumps; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D012074:Remission Induction; D013997:Time Factors
D000873:Anthracenes; D000970:Antineoplastic Agents; C031404:bisantrene